NASDAQ$MNKD

MannKind Corp · Q1 2026 earnings

Q1 2026 earnings · · Investor relations

Briefing

MannKind reported Q1 2026 total revenue of $90.2M and a net loss of $16.6M, with basic loss per share of $0.05.

Total revenues grew to $90.2 million from $78.4 million, led by Afrezza commercial sales of $33.9 million and royalties of $32.7 million. The company posted a net loss of $16.6 million, or $0.05 per basic share, versus net income of $13.2 million a year ago as higher SG&A and interest on financing liabilities increased. Operating loss was $1.7 million.

  • Total revenue $90.2M (+15% YoY).
  • Commercial product sales $33.9M; royalties $32.7M.
  • Net loss $(16.6)M vs. $13.2M income prior year.
  • scPharma acquisition closed October 2025.

Headline financials

Total Revenue

$90.2M

Previous: $78.4M+15.1%
EPS (adj)

-$0.05

Previous: $0.04-225.0%
Capital Expenditures

-$1.88M

Previous: -$330K-469.7%
Net Income

-$16.6M

Previous: $13.2M-226.3%
Operating Income

-$1.67M

Previous: $22.3M-107.5%

Revenue & EPS history

MannKind · Revenue · Quarterly

$90.2M

Q1 2026+15.1%vs Q1 2025
Beat estimate in 13 of 15 quarters(87%)
ActualEstimate

Revenue by segment

MannKind · $31M total across 3 segments · Q3 2023

  • Afrezza
    $13.5M
  • Collaborations and services
    $13.1M
  • V-Go
    $4.45M

Forward guidance

Management highlights Afrezza uptake and Tyvaso DPI royalty stream; no numeric FY EPS guide in the 10-Q.

Tailwinds

  • Double-digit total revenue growth.
  • Royalty and collaboration revenue diversification.
  • Near break-even operating income.

Headwinds

  • Swing to net loss on higher SG&A and interest.
  • Integration of scPharma adds complexity.
  • Commercial execution and payer access risk.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2026

Historical avgQ1 2026

-0.4%

Avg return

Earnings day

-0.7%

Avg return

5 days after

+1.5%

Avg return

30 days after

39%

25 / 64 earnings

Positive

+44.9%

Q3 2016

Best reaction

-28.5%

Q1 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+24.5%+17.5%+18.5%
Q4 2025-6.9%-16.3%-34.9%
Q3 2025+10.6%-1.1%+3.6%
Q1 2025-4.5%-2.7%-9.7%
Q4 2024-4.4%-5.9%-8.0%
Q3 2024-1.2%-4.8%-8.6%
Q2 2024-1.5%-1.5%+12.5%
Q1 2024-3.6%-1.3%+4.5%
Q4 2023+9.5%+25.7%+26.5%
Q3 2023-0.8%-6.8%-0.3%
Q2 2023+15.5%+11.2%-3.8%
Q1 2023+13.4%+9.0%+6.2%
Q4 2022+4.2%+1.7%-23.1%
Q3 2022+6.3%+20.7%+32.8%
Q2 2022-1.4%-4.6%-9.0%
Q1 2022-8.7%-8.7%+42.7%
Q4 2021-25.7%-24.9%-5.2%
Q3 2021-0.6%+3.1%-14.3%
Q2 2021+5.1%+5.4%+20.8%
Q1 2021-8.4%-3.9%-8.0%
Q4 2020-4.5%-36.8%-40.0%
Q3 2020+8.8%+19.0%+43.9%
Q2 2020+0.0%-4.2%-1.2%
Q1 2020-2.2%-0.7%+4.5%
Q4 2019-7.9%-16.4%-27.6%
Q3 2019-15.1%-16.8%-18.8%
Q2 2019-0.9%+4.6%+13.9%
Q1 2019-12.3%-19.4%-25.2%
Q4 2018+23.8%+17.2%+27.8%
Q3 2018+0.0%-1.1%-2.7%
Q2 2018-26.8%-29.3%-29.9%
Q1 2018+2.3%+8.7%+13.3%
Q4 2017-10.4%-13.5%-30.3%
Q3 2017-7.1%+0.3%-4.3%
Q2 2017-5.7%-2.5%+61.5%
Q1 2017+13.8%-5.4%+39.3%
Q4 2016+9.9%+2.5%-34.2%
Q3 2016+44.9%+51.2%+51.2%
Q2 2016-6.2%+2.0%-27.6%
Q1 2016-28.5%
Q4 2015+6.0%
Q3 2015-19.9%
Q2 2015+4.5%
Q1 2015-8.4%
Q4 2014+2.8%
Q3 2014-1.5%
Q2 2014-8.0%
Q1 2014+5.8%
Q4 2013+5.9%
Q3 2013+7.3%
Q2 2013-5.1%
Q1 2013+11.0%
Q4 2012-1.9%
Q3 2012+2.6%
Q2 2012+3.9%
Q1 2012-8.3%
Q4 2011+7.9%
Q3 2011-1.6%
Q2 2011-10.1%
Q1 2011-11.8%
Q4 2010-5.5%
Q3 2010-2.3%
Q2 2010-0.7%
Q1 2010+3.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro